Kinesio Taping for Balance and Function in Low Back Pain (KTFB-NSLBP)

June 24, 2025 updated by: Elif Dilara Durmaz

A Randomized Controlled Trial on the Effect of Kinesio Taping on Balance and Functionality in Patients With Nonspecific Low Back Pain

This study aims to examine the effects of kinesiology taping on balance and functional ability in individuals with nonspecific low back pain. Nonspecific low back pain is a common condition that is not linked to a specific medical cause and is often associated with balance problems, reduced physical function, and psychological challenges. In this study, 35 patients aged between 18 and 65 were included. One group received kinesiology taping along with physiotherapy, while the other group received only physiotherapy.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Nonspecific low back pain (NSLBP) is a common musculoskeletal condition that cannot be attributed to a specific pathology. It often leads to limitations in functional activities, impaired balance, and psychological distress, such as depressive symptoms. This study investigates the effects of kinesiology taping on balance and functional outcomes in individuals diagnosed with NSLBP.

The study was conducted on 35 participants aged 18 to 65 years. Participants were randomly assigned to two groups: the intervention group received kinesiology taping in combination with physiotherapy, while the control group received only physiotherapy treatment. Various outcome measures were used to assess the effects of the interventions, including the Visual Analog Scale (VAS) for pain intensity, Functional Rating Index (FRI), Modified Oswestry Disability Index (MODI), Beck Depression Inventory (BDI), Nottingham Health Profile (NHP), and the Flamingo Balance Test.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
35

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Istinye Universyt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aged between 18 and 65 years
  • Diagnosis of nonspecific low back pain
  • Duration of low back pain longer than 6 weeks
  • Ability to attend an outpatient physiotherapy program

Exclusion Criteria:

  • History of spinal surgery
  • Presence of neurological deficits on physical examination
  • Contraindication to kinesiology taping
  • Pregnancy
  • Cardiovascular or pulmonary diseases that contraindicate exercise
  • History of lower extremity surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Kinesiology Taping + Physiotherapy
Participants in this group received kinesiology taping applied to the lumbar region in addition to a physiotherapy program that included therapeutic exercises and modalities tailored for nonspecific low back pain. The intervention aimed to improve balance, reduce pain, and enhance functional outcomes.
Device: Kinesiology Taping
Kinesiology taping was applied to the lumbar area of the participants in the intervention group. The taping aimed to improve posture, reduce pain, and enhance balance and functional performance.
Other: Physiotherapy
The physiotherapy program included therapeutic exercises and physical modalities (such as stretching, strengthening, and posture training) tailored for individuals with nonspecific low back pain.
Active Comparator: Physiotherapy Only
Participants in this group received only the physiotherapy program, which included therapeutic exercises and modalities commonly used in the treatment of nonspecific low back pain. No kinesiology taping was applied in this group.
Other: Physiotherapy
The physiotherapy program included therapeutic exercises and physical modalities (such as stretching, strengthening, and posture training) tailored for individuals with nonspecific low back pain.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Functional Rating Index (FRI) score
Time Frame: Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Functional status was assessed using the Functional Rating Index (FRI) to evaluate the level of functional disability related to nonspecific low back pain. A decrease in the score indicates improved functional status.
Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Visual Analog Scale (VAS) score for pain
Time Frame: Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Pain intensity was evaluated using the Visual Analog Scale. A decrease in score indicates reduced pain severity.
Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Change in Flamingo Balance Test (FBT) score
Time Frame: Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Balance was assessed using the Flamingo Balance Test. Improved performance indicates better postural control and balance.
Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Change in Beck Depression Inventory (BDI) score
Time Frame: Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Psychological status was assessed using the Beck Depression Inventory. A decrease in score reflects improved mood and reduced depressive symptoms.
Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Change in Oswestry Disability Index (ODI) score
Time Frame: Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Disability level related to low back pain was evaluated using the Oswestry Disability Index. A decrease in score reflects improved functional ability.
Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Change in Nottingham Health Profile (NHP) score
Time Frame: Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)
Health-related quality of life was evaluated using the Nottingham Health Profile. A decrease in score indicates better quality of life.
Baseline (Day 1)": Initial assessment (Day 1 of the study) "3 weeks post-intervention": Second assessment, 3 weeks after the intervention (after the treatment program)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Elif Dilara Durmaz

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 20, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 15, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 20, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 19, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 20, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 26, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 24, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ISU_NSLBP_KT_2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings